facebook
twitter
search
search

Actavis to buy rival Warner Chilcott

May 20, 2013 at 2:06 PM

ZUG, Switzerland, May 20 (UPI) -- Swiss generic drug producer Actavis said it would buy U.S. rival Warner Chilcott for a deal valued at $5 billion.

It is an all-stock deal that provides a premium 5 percent on Warner Chilcott's closing price Friday. Actavis said in a release it agreed to pay 0.16 of a share for each Warner Chilcott share, which comes to $20.08 per share.

Actavis will assume Warner Chilcott's $3.5 billion long-term debt, as well, The New York Times reported.

"We have set as our strategic corporate objective to build a leading global specialty pharmaceutical company," Paul Bisaro, Actavis' chief executive, said in a statement.

Anecdotes back that up. Last month, talks to have Actavis sell itself to Valeant Pharmaceuticals collapsed. Meanwhile, the Actavis board turned down offers from others, including Mylan, a source told the Times.

Bisaro said Actavis and Warner Chilcott together "creates a strong specialty brand portfolio focused in therapeutic categories with strong growth potential."

"And [it] is supported by a deep pipeline of development programs," he said.

Latest Headlines
Top Stories
Australia receives seventh C-17 in record time
Crude oil prices extend losses
Turkish oil pipeline from Iraq bombed
Greenpeace again stands in Shell's way to arctic
Work to prepare Portsmouth Navy base for new carriers begins